Nice presentation by #PhD candidate Denise Abbel about the complex choice to use #antithrombotic therapy in patients with #cancer in the last phase of life:
✅ prevention of thrombic events
❌ risk of bleeding
❓what is more important?
Nice presentation by #PhD candidate Denise Abbel about the complex choice to use #antithrombotic therapy in patients with #cancer in the last phase of life:
✅ prevention of thrombic events
❌ risk of bleeding
❓what is more important?
🥳 Thrilled to share our latest publication in #Thrombosis Research!
📖 Emily Martens led this important study on #deprescribing #antithrombotic therapy in end-of-life #cancer care
❗ Lots of practice variation across #Europe
➡️ More #evidence needed
A #snakevenom-analog #peptide that inhibits #SARSCoV2 and papain-like protease displays #antithrombotic activity in #mice #arterial # thrombosis model, without interfering with #bleeding time
https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-022-00436-5
https://thrombosisjournal.biomedcentral.com/counter/pdf/10.1186/s12959-022-00436-5.pdf
Background (p-BthTX-I)2 K, a dimeric analog peptide derived from the C-terminal region of phospholipase A2-like bothropstoxin-I (p-BthTX-I), is resistant to plasma proteolysis and inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains with weak cytotoxic effects. Complications of SARS-CoV-2 infection include vascular problems and increased risk of thrombosis; therefore, studies to identify new drugs for treating SARS-CoV-2 infections that also inhibit thrombosis and minimize the risk of bleeding are required. Objectives To determine whether (p-BthTX-I)2 K affects the hemostatic system. Methods Platelet aggregation was induced by collagen, arachidonic acid, and adenosine diphosphate (ADP) in the Chronolog Lumi-aggregometer. The coagulation activity was evaluated by determining activated partial thromboplastin clotting time (aPTT) and prothrombin time (PT) with (p-BthTX-I)2 K (5.0–434.5 µg) or 0.9% NaCl. Arterial thrombosis was induced with a 540 nm laser and 3.5–20 mg kg− 1 Rose Bengal in the carotid artery of male C57BL/6J mice using (p-BthTX-I)2 K. Bleeding time was determined in mouse tails immersed in saline at 37 °C after (p-BthTX-I)2 K (4.0 mg/kg and 8.0 mg/kg) or saline administration. Results (p-BthTX-I)2 K prolonged the aPTT and PT by blocking kallikrein and FXa-like activities. Moreover, (p-BthTX-I)2 K inhibited ADP-, collagen-, and arachidonic acid-induced platelet aggregation in a dose-dependent manner. Further, low concentrations of (p-BthTX-I)2 K extended the time to artery occlusion by the formed thrombus. However, (p-BthTX-I)2 K did not prolong the bleeding time in the mouse model of arterial thrombosis. Conclusion These results demonstrate the antithrombotic activity of the peptide (p-BthTX-I)2 K possibly by kallikrein inhibition, suggesting its strong biotechnological potential.